BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting21-09-2020
21-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on 'Biocon Biologics Transforming Healthcare. Transforming Lives.'18-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting17-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting15-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting07-09-2020
Your Stock Portfolio: Biocon in a long-term uptrend
Investors looking for the long haul can buy the stock in declines with a stop-loss at 29006-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting04-09-2020
Biocon Biologics sees big opportunity in US for its insulin injection
Biocon Biologics India, a subsidiary of Biocon, is engaged in developing affordable biosimilars. The company along with Mylan recently announced the04-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting04-09-2020
BIOCON LTD. - 532523 - Allotment Of Shares By Biocon Biologics India Limited ("BBIL") To Tata Capital Growth Fund II ("Investor").
Dear Sir/ Madam, Further to our intimation dated August 3, 2020, in relation to execution of a share subscription agreement ('SSA') and a shareholders' agreement ('SHA') between Biocon Limited (the 'Company'), Biocon Biologics India Limited ('BBIL'), Activ Pine LLP ('Existing Investor') and Tata Capital Growth Fund II ('Investor') as applicable, we wish to inform you that the subscription money aggregating to Rs. 225 Crores have been received by BBIL from the Investor. Consequently, the Board of BBIL has approved the allotment of 88,30,456 (Eighty Eight Lakh Thirty Thousand Four Hundred Fifty Six) equity shares of Rs. 10/- each at an issue price of Rs. 254.80/- per equity share (including a premium of Rs. 244.80/- per equity share) to the Investor.03-09-2020